非去极化肌松药抵抗:起效时间延长系统综述
该系统综述纳入25项随机对照试验和队列研究,评估对非去极化肌松药(NDMRs)抵抗的患者群体。强证据支持热损伤和Duchenne肌营养不良患者罗库溴铵起效延长;中等证据支持低体温、感染、眼咽型肌营养不良、终末期肾病儿童、先天性心脏缺损及部分用药情况下NDMRs起效延长。
要点
- 热损伤和Duchenne肌营养不良患者应怀疑罗库溴铵起效延长。
- 低体温、感染、眼咽型肌营养不良等情况下NDMRs起效可能延长。
- 终末期肾病儿童和先天性心脏缺损患者NDMRs起效可能延长。
核心结论
- 热损伤和Duchenne肌营养不良患者应怀疑NDMRs起效延长。
- 感染、眼咽型肌营养不良、先天性心脏缺损、肾衰竭、接受ulinastatin治疗的肝硬化等情况下证据支持NDMRs起效延长。
研究设计与样本
- 系统综述,纳入随机对照试验和队列研究,共25项研究。
- 2016年在PubMed和EMBASE进行综合检索。
主要发现
- 强证据支持热损伤和Duchenne肌营养不良患者罗库溴铵起效时间延长。
- 中等证据支持低体温、感染、眼咽型肌营养不良、接受ulinastatin治疗的肝硬化、先于NDMR给予瑞芬太尼、禁食患者NDMR前静脉补液、终末期肾病儿童及房室间隔缺损患者NDMRs起效延长。
关键数值与推荐
- 起效时间延长定义为与对照组相比差异超过25%。
- 起效时间定义为给予NDMR至四个成串刺激中第一个颤搐基线高度最大抑制(90%、95%或100%)的时间。
临床怎么用
- 对热损伤和Duchenne肌营养不良患者应预期NDMRs起效延长并调整给药策略。
- 对感染、低体温、眼咽型肌营养不良、终末期肾病儿童、先天性心脏缺损等患者也应警惕NDMRs起效延长。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nondepolarising muscle relaxants (NDMRs) provide optimal conditions for tracheal intubation and improve surgical conditions. Several clinical conditions, diseases and pharmacological interactions have been suggested to cause resistance towards NDMRs that may translate into difficult intubation or inadequate operating conditions during surgery. OBJECTIVE: The aim of this study was to evaluate the current evidence of patient groups with resistance towards NDMRs. A prolonged onset time was defined as a difference that exceeded 25% compared with controls. DESIGN: A systematic review of randomised controlled trials and cohort studies. DATA SOURCES: A comprehensive search was performed in 2016 in PubMed and EMBASE. ELIGIBILITY CRITERIA: Patients with conditions or diseases, or patients taking medication, which lead to resistance towards current NDMRs (rocuronium, vecuronium, cisatracurium, atracurium, mivacurium and pancuronium). Included outcomes were onset time defined as the time between administration of NDMR to maximal (90, 95 or 100%) depression of baseline twitch height of the first twitch in a train-of-four. RESULTS: Twenty-five studies were included. Strong evidence supports a prolonged onset time of rocuronium in patients with thermal injury and Duchenne muscular dystrophy. Moderate evidence supports a prolonged onset time of NDMRs during hypothermia and in patients with infection, oculopharyngeal muscular dystrophy, liver cirrhosis treated with ulinastatin, when remifentanil is administered prior to administration of an NDMR, in fasting patients being rehydrated intravenously prior to administration of NDMR, in children with end-stage renal failure and in patients with atrial or ventricular septal defects. CONCLUSION: A prolonged onset time should be suspected in patients with thermal injury and Duchenne's muscular dystrophy. Further, evidence supports a prolonged onset time in patients with infection, oculopharyngeal muscular dystrophy, congenital heart defects, kidney failure, liver cirrhosis treated with ulinastatin along with remifentanil or intravenous fluids administered prior to NDMR.
引用
- Mørk EL, Kristensen ML, Stokholm JB, et al. Resistance towards nondepolarising muscle relaxants: prolonged onset time: A systematic review. Eur J Anaesthesiol. 2019. PMID: 30950905. doi:10.1097/EJA.0000000000000991
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。